1. Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, Park A,Aguilar J, Ernstoff E, Charati M, Dushin R, Aujay M, Lee C, Ramoth H, Milton M,Hampl J, Lazetic S, Pulito V, Rosfjord E, Sun Y, King L, Barletta F, Betts A,Guffroy M, Falahatpisheh H, O'Donnell CJ, Stull R, Pysz M, Escarpe P, Liu D,Foord O, Gerber HP, Sapra P, Dylla SJ. A PTK7-targeted antibody-drug conjugatereduces tumor-initiating cells and induces sustained tumor regressions. SciTransl Med. 2017 Jan 11;9(372):eaag2611. doi: 10.1126/scitranslmed.aag2611.PMID: 28077676.
2.Jin Z, Guo T, Zhang X, Wang X, Liu Y. PTK7: an underestimated contributor tohuman cancer. Front Oncol. 2024 Oct 15;14:1448695. doi:10.3389/fonc.2024.1448695. PMID: 39474113; PMCID: PMC11518688.
3.Frenster JD, Erdjument-Bromage H, Stephan G, Ravn-Boess N, Wang S, Liu W,Bready D, Wilcox J, Kieslich B, Jankovic M, Wilde C, Horn S, Sträter N,Liebscher I, Schöneberg T, Fenyo D, Neubert TA, Placantonakis DG. PTK7 is apositive allosteric modulator of GPR133 signaling in glioblastoma. Cell Rep.2023 Jul 25;42(7):112679. doi: 10.1016/j.celrep.2023.112679. Epub 2023 Jun 23.PMID: 37354459; PMCID: PMC10445595.